Genfit's GFT505 meets Phase II endpoints

Genfit S.A. (Euronext:ALGFT) said GFT505 met the co-primary endpoints in the Phase II GFT505-2083 trial to treat atherogenic dyslipidemia. On the co-primary endpoints, GFT505 significantly reduced plasma triglycerides by 21% compared with placebo (p=0.0027) and increased HDL-C by 9% compared with placebo (p=0.003). The double-blind, international trial enrolled 97 pre-diabetics with atherogenic dyslipidemia and abdominal obesity. ...